These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 16858958)
21. Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 1200 mg/day) in a Q.I.D. regimen. Chadwick DW; Betts TA; Boddie HG; Crawford PM; Lindstrom P; Newman PK; Soryal I; Wroe S; Holdich TA Seizure; 2002 Mar; 11(2):114-23. PubMed ID: 11945098 [TBL] [Abstract][Full Text] [Related]
22. Oxcarbazepine monotherapy in children and adolescents: a single-center clinical experience. Kothare SV; Khurana DS; Mostofi N; Melvin JJ; Marks HG; Valencia I; Legido A Pediatr Neurol; 2006 Oct; 35(4):235-9. PubMed ID: 16996394 [TBL] [Abstract][Full Text] [Related]
23. Risk factors of oxcarbazepine-induced hyponatremia in patients with epilepsy. Lin CH; Lu CH; Wang FJ; Tsai MH; Chang WN; Tsai NW; Lai SL; Tseng YL; Chuang YC Clin Neuropharmacol; 2010; 33(6):293-6. PubMed ID: 20881597 [TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Beydoun A; Uthman BM; Kugler AR; Greiner MJ; Knapp LE; Garofalo EA; Neurology; 2005 Feb; 64(3):475-80. PubMed ID: 15699378 [TBL] [Abstract][Full Text] [Related]
25. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy. Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453 [TBL] [Abstract][Full Text] [Related]
26. Pregabalin or placebo used adjunctively with levetiracetam in refractory partial-onset epilepsy: a post hoc efficacy and safety analysis in combined clinical trials. Uthman BM; Almas M; Emir B; Giordano S; Leon T Curr Med Res Opin; 2011 Jul; 27(7):1285-93. PubMed ID: 21561392 [TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Elger C; Halász P; Maia J; Almeida L; Soares-da-Silva P; Epilepsia; 2009 Mar; 50(3):454-63. PubMed ID: 19243424 [TBL] [Abstract][Full Text] [Related]
28. Comparison of twice- and three times daily tiagabine for the adjunctive treatment of partial seizures in refractory patients with epilepsy: an open label, randomised, parallel-group study. Biraben A; Beaussart M; Josien E; Pestre M; Savet JF; Schaff JL; Tourniaire D; Sevestre M; Renault-Djouadi J Epileptic Disord; 2001 Jun; 3(2):91-100. PubMed ID: 11431171 [TBL] [Abstract][Full Text] [Related]
30. Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial. Peltola J; Coetzee C; Jiménez F; Litovchenko T; Ramaratnam S; Zaslavaskiy L; Lu ZS; Sykes DM; Epilepsia; 2009 Mar; 50(3):406-14. PubMed ID: 19317886 [TBL] [Abstract][Full Text] [Related]
31. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial. Husain A; Chung S; Faught E; Isojarvi J; McShea C; Doty P Epilepsia; 2012 Mar; 53(3):521-8. PubMed ID: 22372628 [TBL] [Abstract][Full Text] [Related]
32. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures. Wu XY; Hong Z; Wu X; Wu LW; Wang XF; Zhou D; Zhao ZX; Lv CZ Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of levetiracetam: a review of three pivotal clinical trials. Privitera M Epilepsia; 2001; 42 Suppl 4():31-5. PubMed ID: 11564123 [TBL] [Abstract][Full Text] [Related]
34. Spotlight on oxcarbazepine in epilepsy. Bang LM; Goa KL CNS Drugs; 2004; 18(1):57-61. PubMed ID: 14731060 [TBL] [Abstract][Full Text] [Related]
35. Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode. Benedetti A; Lattanzi L; Pini S; Musetti L; Dell'Osso L; Cassano GB J Affect Disord; 2004 Apr; 79(1-3):273-7. PubMed ID: 15023507 [TBL] [Abstract][Full Text] [Related]
37. Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. Shinnar S; Pellock JM; Conry JA Eur J Paediatr Neurol; 2009 Jan; 13(1):3-9. PubMed ID: 18343174 [TBL] [Abstract][Full Text] [Related]
38. Long-term treatment with oxcarbazepine in clinical practice. Passarella B; Nozzoli C Funct Neurol; 2005; 20(3):131-3. PubMed ID: 16324237 [TBL] [Abstract][Full Text] [Related]
39. Oxcarbazepine long-term treatment retention in patients switched over from carbamazepine. Albani F; Baruzzi A; Neurol Sci; 2006 Jul; 27(3):173-5. PubMed ID: 16897629 [TBL] [Abstract][Full Text] [Related]